Gene therapy for HIV-1 infection is an option and perhaps an adjuvant to conventional drug therapy. We have developed an RNA based therapeutic strategy that utilizes hammerhead ribozymes targeted to the tat and rev genes of HIV-1. The genes encoding the ribozymes have been expressed as part of a polycistronic transcript originating form the LTR of an LN based retroviral vector. In pre-clinical trials primary hematopoietic progenitor cells transduced with the ribozyme based vectors gave rise to monocytic cells which are resistant to HIV-1 challenge. This vector- ribozyme combination is currently being utilized in a phase I clinical trial of HIV-1 infected individuals infected with autologous ribozyme and vector transduced CD34 cells. The results obtained thus far have demonstrated limited marking with the ribozyme and vector constructs. Those early trials did not monitor efficacy. In the proposed clinical trials, efficacy, and hence long term expression of the ribozymes will be an important issue. In this project we will be developing improved systems for expressing ribozyme and Rev binding aptamers from the backbone of a modified amphotropic retroviral vector, MND neo. Several different Pol II and Pol III promoters, and combinations of ribozymes and Rev binding aptamers will be examined for levels and duration of expression and anti- viral activity. New ribozyme targets will be identified using a facile method for ribozyme site selection on native mRNAs in cell extracts. These new ribozymes trials: Combinations of promoter, ribozyme, and aptamers will be tested in long term bone marrow cultures and a SCID-hu mouse. The most promising cassettes will be channeled into project 3. Constructs in the MND vector which show efficacy and long term expression will be tested in project 1 and ultimately utilized in the human clinical trial of project 4. The long range objectives of this project are the development of expression systems for therapeutic RNAs which are applicable to treatment of HIV-1 in a gene therapy setting.
| Saetrom, Pål; Biesinger, Jacob; Li, Sierra M et al. (2009) A risk variant in an miR-125b binding site in BMPR1B is associated with breast cancer pathogenesis. Cancer Res 69:7459-65 |
| Kowolik, Claudia M; Yam, Priscilla; Yu, Ying et al. (2003) HIV vector production mediated by Rev protein transduction. Mol Ther 8:324-31 |
| Li, Ming-Jie; Bauer, Gerhard; Michienzi, Alessandro et al. (2003) Inhibition of HIV-1 infection by lentiviral vectors expressing Pol III-promoted anti-HIV RNAs. Mol Ther 8:196-206 |
| Paul, Cynthia P; Good, Paul D; Li, Shirley X L et al. (2003) Localized expression of small RNA inhibitors in human cells. Mol Ther 7:237-47 |
| Strayer, David; Branco, Francisco; Zern, Mark A et al. (2002) Durability of transgene expression and vector integration: recombinant SV40-derived gene therapy vectors. Mol Ther 6:227-37 |
| Lee, Nan Sook; Dohjima, Taikoh; Bauer, Gerhard et al. (2002) Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells. Nat Biotechnol 20:500-5 |
| Yam, Priscilla Y; Li, Shulian; Wu, Jerry et al. (2002) Design of HIV vectors for efficient gene delivery into human hematopoietic cells. Mol Ther 5:479-84 |
| Michienzi, Alessandro; Li, Shirley; Zaia, John A et al. (2002) A nucleolar TAR decoy inhibitor of HIV-1 replication. Proc Natl Acad Sci U S A 99:14047-52 |
| Chang, Zongli; Westaway, Shawn; Li, Shirley et al. (2002) Enhanced expression and HIV-1 inhibition of chimeric tRNA(Lys3)-ribozymes under dual U6 snRNA and tRNA promoters. Mol Ther 6:481-9 |
| Michienzi, A; Rossi, J J (2001) Intracellular applications of ribozymes. Methods Enzymol 341:581-96 |
Showing the most recent 10 out of 12 publications
